Anti-Infection
Anti-Infection
With decades of experience in anti-infective therapeutics, we have built a strong portfolio and core technical strengths. Our pipeline features leading products targeting respiratory tract infections, fungal diseases, and other major infection-related indications.
Innovation Drug Pipeline
Projects
Target
Indications
PCC
IND
Phase I/II
Phase III
NDA
Launched
Projects：
GP681（Suraxavir Marboxil Tables）
Target：
PA
Indications：
influenza
Projects
Target
Indications
PCC
IND
Phase I/II
Phase III
NDA
Launched
On March 27, 2025, Suraxavir Marboxil Tablets (brand name: Yisuda) received marketing approval from the National Medical Products Administration (NMPA). It is indicated for the treatment of uncomplicated influenza A and B in previously healthy adolescents and adults aged 12 and older.
Phase III clinical trial data were published in the prestigious global medical research journal Nature Medicine.
Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.
Nature Medicine, 2025 Jan 7.
doi: 10.1038/s41591-024-03419-3
ClinicalTrials.gov registration: NCT05474755.
Projects：
GP681(Dry Suspension)
Target：
PA
Indications：
influenza
Projects
Target
Indications
PCC
IND
Phase I/II
Phase III
NDA
Launched
Projects：
KR24258
Target：
-
Indications：
-
Projects
Target
Indications
PCC
IND
Phase I/II
Phase III
NDA
Launched
Marketed Products
Xinyang® Abiraterone Acetate Tablets
Xinyang® Abiraterone Acetate Tablets are a highly selective CYP17 enzyme inhibitor that targets multiple sites of androgen biosynthesis throughout the body.
Ligesitai® Sorafenib Tosylate Tablets
Ligesitai® Sorafenib Tosylate Tablets are a multi-target oral medication for treating tumors, with dual mechanisms of action. It inhibits tumor angiogenesis by blocking VEGFR and PDGFR and suppresses tumor cell proliferation by blocking the Raf/MEK/ERK signaling pathway, indirectly inhibiting tumor cell growth. It was approved for market in August 2020. It is primarily used for the treatment of renal cancer, liver cancer, and thyroid cancer.
Xinzhuo® Afatinib Dimaleate Tablets
Xinzhuo® Afatinib Dimaleate Tablets are the first irreversible ErbB family receptor blockers. They covalently bind to the kinase regions of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4), irreversibly inhibiting tyrosine kinase autophosphorylation, leading to downregulation of ErbB signaling and inhibiting tumor cell proliferation. Xinchuo® was approved for market in August 2021 and is indicated for: Locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR gene-sensitive mutations in patients who have not previously received EGFR tyrosine kinase inhibitors (TKI) treatment. Locally advanced or metastatic squamous cell carcinoma of non-small cell lung cancer (NSCLC) with disease progression during or after platinum-based chemotherapy.
